On Monday, Molbio Diagnostics launched “Truenat” the H3N2/H1N1 diagonistic test for the differential identification of the H3N2 and H1N1 viruses. The Central Drugs Standard Control Organization (CDSCO) has approved the test, which may produce results in an hour.

Truenat H3N2/H1N1 is the first point-of-care Real-Time PCR test that aids in the confirmed diagnosis of influenza infections, according to the diagnostics business. The test will run on current Truenat equipment in over 3500 PHCs/CHCs and over 1200 private labs and hospitals across India, allowing patients to receive a rapid diagnosis at all levels of the healthcare chain.

India is seeing increased influenza virus infections caused by H3N2 and H1N1. The viruses that transmit through the air can maintain human-to-human transmission, which can potentially produce an influenza pandemic.

The diagnostics firm stated that when molecular technologies such as Polymerase Chain Reaction (PCR) and Real-Time PCR were transforming the diagnosis and management of several diseases, Truenat has been a game changer. Truenat is a point-of-care, portable, battery-powered, IoT-enabled, multi-disease, Real-Time PCR platform that provides tests for over 40 diseases, such as Dengue, Malaria, Influenza, Nipah, COVID-19, tuberculosis, Hepatitis-C-Virus, Hepatitis-B-Virus, human immunodeficiency viruses (HIV) , human papillomavirus (HPV), and Typhoid at the point of care.

 (Source: https://www.financialexpress.com/healthcare/diagnostic/molbio-diagnostics-launches-truenat-test-for-h3n2-and-h1n1-virus/3031398/#:~:text=Molbio%20Diagnostics%20on%20Monday%20announced%20that%20it%20has,and%20can%20provide%20sample-to-result%20in%20an%20hour’s%20time.)